EP3816327B1 - Verfahren zur herstellung von porösen antibakteriellen beschichtungen auf der oberfläche von titan und titanlegierungen - Google Patents
Verfahren zur herstellung von porösen antibakteriellen beschichtungen auf der oberfläche von titan und titanlegierungen Download PDFInfo
- Publication number
- EP3816327B1 EP3816327B1 EP20460021.7A EP20460021A EP3816327B1 EP 3816327 B1 EP3816327 B1 EP 3816327B1 EP 20460021 A EP20460021 A EP 20460021A EP 3816327 B1 EP3816327 B1 EP 3816327B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- titanium
- mol
- oxidation
- plasma
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 57
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 title claims description 35
- 239000010936 titanium Substances 0.000 title claims description 35
- 229910052719 titanium Inorganic materials 0.000 title claims description 33
- 238000000576 coating method Methods 0.000 title description 28
- 230000000844 anti-bacterial effect Effects 0.000 title description 17
- 229910001069 Ti alloy Inorganic materials 0.000 title description 9
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000006056 electrooxidation reaction Methods 0.000 claims description 27
- 229910001382 calcium hypophosphite Inorganic materials 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000012266 salt solution Substances 0.000 claims description 6
- 229910000153 copper(II) phosphate Inorganic materials 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 229910000161 silver phosphate Inorganic materials 0.000 claims description 5
- 229910000165 zinc phosphate Inorganic materials 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- GQDHEYWVLBJKBA-UHFFFAOYSA-H copper(ii) phosphate Chemical compound [Cu+2].[Cu+2].[Cu+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GQDHEYWVLBJKBA-UHFFFAOYSA-H 0.000 claims description 2
- 229910001463 metal phosphate Inorganic materials 0.000 claims description 2
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 claims description 2
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 claims description 2
- 238000007745 plasma electrolytic oxidation reaction Methods 0.000 description 24
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 17
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 16
- 239000011575 calcium Substances 0.000 description 15
- 239000007943 implant Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 12
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 12
- 239000011701 zinc Substances 0.000 description 11
- 229910045601 alloy Inorganic materials 0.000 description 10
- 239000000956 alloy Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000010949 copper Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000003792 electrolyte Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 229910052709 silver Inorganic materials 0.000 description 6
- 239000004332 silver Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 238000005260 corrosion Methods 0.000 description 5
- 230000007797 corrosion Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229910052882 wollastonite Inorganic materials 0.000 description 4
- 229910000861 Mg alloy Inorganic materials 0.000 description 3
- 238000007743 anodising Methods 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 3
- 229940095618 calcium glycerophosphate Drugs 0.000 description 3
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000005749 Copper compound Substances 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000002048 anodisation reaction Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 229910052911 sodium silicate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229910003243 Na2SiO3·9H2O Inorganic materials 0.000 description 1
- 229910021205 NaH2PO2 Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229910000883 Ti6Al4V Inorganic materials 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- FWZLXRFUDMNGDF-UHFFFAOYSA-N [Co].[Cu]=O Chemical compound [Co].[Cu]=O FWZLXRFUDMNGDF-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical class [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002065 inelastic X-ray scattering Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001699 photocatalysis Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000010456 wollastonite Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- 229910052845 zircon Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D11/00—Electrolytic coating by surface reaction, i.e. forming conversion layers
- C25D11/02—Anodisation
- C25D11/026—Anodisation with spark discharge
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D11/00—Electrolytic coating by surface reaction, i.e. forming conversion layers
- C25D11/02—Anodisation
- C25D11/26—Anodisation of refractory metals or alloys based thereon
Definitions
- the subject of this invention is a formation method of the porous oxide layers on the surface of titanium and titanium alloys by plasma electrochemical oxidation. Due to the oxidation in baths containing suspended, insoluble particles of silver, copper or zinc compounds, the obtained oxide layers are intended to be characterized antimicrobial and/or bacteriostatic properties.
- Titanium and titanium alloys are used as long-term implant materials characterized by good biocompatibility with hard and soft tissue of the human body.
- bactericides such as antibiotics.
- a good example of different than antibiotics bactericides can be the modified implant biomaterials containing silver or copper in their composition. So far in the literature, there are known studies of obtaining layers containing silver or copper compounds formed from soluble forms of these elements compounds.
- the patent no. CN 101899700 describes the method of obtaining bioactive coatings on the surface of titanium and magnesium alloys by the plasma electrochemical oxidation using bath consisting of AgNO 3 , which results in the formation of porous oxide layers containing calcium, phosphorus and silver improving the bioactivity of the coatings, as well as their corrosion resistance and decreasing the risk of bacterial infections caused by implantation processes.
- the thickness of the coating formed on the surface of the titanium alloy measured 50-85 ⁇ m, the porosity of the coating was in the range from 20% to 30%, and the determined adhesion of the coating to the substrate was 23-40 MPa.
- the patent no. CN 108543109 describes the formation method of composite materials with antibacterial properties.
- the composite consists of ceramic TiO 2 and silver nanoparticles on the surface of a titanium alloy intended for use as the implant for bone tissue.
- a titanium alloy intended for use as the implant for bone tissue.
- Cimenoglu Materials Science and Engineering, 71 (2017)565 presents the method of plasma electrochemical oxidation using the bath containing Na 2 SiO 3 , NaOH and CH 3 COOAg.
- Characteristics of multi-layer coatings synthesized on Ti6Al4V alloy by micro-arc oxidation in silver nitrate added electrolytes F. Muhaffel, G. Cempura, M. Menekse, A. Czyrska-Filemonowicz, N. Karaguler, H. Cimenoglu, Surface and Coating Technology.
- Cimenoglu Materials Science and Engineering C, 48 (2015) 579
- Corrosion behaviour of Zn-incorporated antibacterial TiO2 porous coating on titanium (X. Zhang, H. Wang, J. Li, X. He, R. Hang, X. Huang, L. Tian, B.
- the patent no. CN103911644 describes the plasma electrochemical oxidation of titanium alloys using baths containing phytic acid or phytate with the addition of electrolytes such as bioactive calcium, magnesium, zinc salts or with the addition of organic compounds such as tannic acid or hydroxides. Chromium(VI) compounds, fluorides and orthophosphates are not used during the process, therefore air polluting products have been limited. As a result of the process, microporous coating structures with good antibacterial properties, bioactivity, corrosion resistance and abrasion resistance are obtained. In the patent no.
- CN1035266261 there is presented the method of obtaining ceramic membranes containing zinc on the surface of titanium or magnesium modified by plasma electrochemical oxidation process using electrolytes containing soluble compounds of zinc and calcium, titanium or magnesium as anodes and stainless steel as cathode.
- the obtained ceramic membranes increase the bioactivity of the titanium or magnesium surface. Additionally, they degrade in the human body environment, causing the increase in immunity of human organism to bacterial infections and supporting the cell growth process in vitro.
- Antibacterial activity and increased bone marrow stem cell functions of Zn-incorporated TiO2 coatings on titanium H. Hu, W. Zhang, Y. Qiao, X. Jiang, X. Liu, C.
- CN 107376897 describes the method of plasma oxidation of electrochemical titanium in the electrolyte containing zinc nanoparticles.
- Preparation and photocatalytic performance of ZnO/WO3/TiO2 composite coatings formed by plasma electrolytic oxidation Q. Honglei, L. Chen, Y. Xiwen, W. Mingyue, Y. Zongcheng, "Journal of Materials Science: Materials in Electronics "(29 (2018) 2060 ) there is known the method of plasma oxidation of electrochemical titanium in the electrolyte containing zinc nanoparticles.
- Sopchenski, K. Popat, P. Soares, "Thin Solid Films” presents the method of anodic electrochemical oxidation in the bath containing Ca(CH 3 COO) 2 , calcium glycerophosphate and Zn(CH 3 COO) 2 .
- the patent no. PL 225226 descibes the method of anodic electrochemical oxidation of tantalum, niobium and zirconium in the suspension of insoluble CaSiO 3 at a concentration of 1-300 g ⁇ dm -3 at the temperature of 15-50°C at the anodic current density of 5-200 mA ⁇ cm -2 and applied voltage of 100-650 V for 1-60 minutes.
- PL 225227 there is presented the method of electrochemical oxidation of plasma titanium and its alloys in a suspension of CaSiO 3 at a concentration of 1-300 g ⁇ dm -3 at the temperature of 15-50°C, at the anodic current density of 5-200 mA ⁇ cm -2 and applied voltage of 100-650 V in time 1-60 minutes.
- PL 396115 there is described the method of electrochemical oxidation of plasma titanium and its alloys in suspension containing ZrSiO 4 at the concentration of 1-100 g ⁇ dm -3 with the addition of the alkali metal hydroxide at the concentration of 5-100 g ⁇ dm -3 at the temperature of 15-50°C, at the anodic current density 5-500 mA ⁇ cm -2 and 1-600 V for 1-30 minutes.
- PL 214630 describes the method of electrochemical plasma oxidation of Ti-xNb-yZr alloys in the Ca(H 2 PO 2 ) 2 solution at the concentration of 1-150 g ⁇ dm -3 or in a NaH 2 PO 2 solution at a concentration of 1-250 g ⁇ dm -3 at the temperature of 15-50°C, at the anodic current density of 5-5000 mA ⁇ cm -2 and applied voltage of 100-650 V for 1-60 minutes.
- the paper " Surface characterisation of Ti-15Mo alloy modified by a PEO process in various suspensions" (A.Kazek-Kesik, G. Dercz, I. Kalemba, K.Suchanek, A. Kukharenko, D. Korotin, J.
- the surface microstructure (SEM, cross-section of coating), roughness and chemical composition (energy dispersive X-ray spectroscopy, thin layer X-ray diffraction, X-ray photo electron spectroscopy and Raman spectroscopy) of the porous oxide layers were investigated.
- the concentration of powder added to the solution changed the chemical composition and morphology of PEO coatings on the Ti-15Mo alloy surface. Calcium and phosphorous compounds were detected in the coatings formed on the substrate by the PEO process at 300V.
- the aim of the invention is to develop a method allowing to obtain the porous oxide layers with incorporated compounds with antibacterial properties.
- the essence of the invention is a method of titanium surface modification by plasma electrochemical oxidation in aqueous Ca(H 2 PO 2 ) 2 baths at a concentration from 0.01 mol ⁇ dm -3 to 5 mol ⁇ dm -3 with an anodic current density from 1 mA ⁇ cm -2 to 250 mA ⁇ cm -2 and applied voltage from 50 V to 600 V, by immersing the element which surface is to be modified in the aqueous Ca(H 2 PO 2 ) 2 solution, characterized in that the bath comprises insoluble particles of metal phosphate at a concentration from 1 g ⁇ dm -3 to 400 g ⁇ dm -3 , and the aqueous salt solution contains copper(II) phosphate Cu 3 (PO 4 ) 2 at a concentration from 1 g ⁇ dm -3 to 400 g ⁇ dm -3 or the aqueous salt solution contains silver(I) phosphate Ag 3 PO 4 at a concentration from 1 g ⁇ dm -3 to 400 g ⁇ dm -3 or
- the invention describes the method of the plasma electrochemical oxidation of titanium and its titanium alloys in suspensions containing insoluble silver or copper compounds in the form of the oxides. In this way, it is possible to obtain porous oxide layers incorporated with particles of compounds characterised by the antibacterial properties.
- An addition of mentioned silver and copper suspension compounds can be a one-step modification of the surface of titanium and its alloys. Thanks to this, there is a chance to eliminate the necessity of high, oral antibiotic delivery route, which is the main cause of increasing bacteria resistance to antibiotics. Additionally, the number of side effects and allergic reactions related to antibiotic treatment can be reduced.
- the surfaces anodised via plasma electrolytic oxidation process are porous and rough, which promotes the proliferation of living cells and supports the osseointegration process.
- Example I The titanium implant, pre-treated by polishing, degreasing, etching and rinsing in demineralised water is placed in the solution containing 0.1 mol ⁇ dm -3 Ca(H 2 PO 2 ) 2 and the suspension of 10 g ⁇ dm -3 Ag 3 PO 4 .
- the electrolytic plasma oxidation process is carried out by polarizing it with the anodic current density of 150 mA ⁇ cm -2 .
- the process is carried out for 5 minutes, with the maximum voltage of 300 V.
- the implant is rinsed in demineralised water and air-dried at 45°C.
- Example II The implant made of Ti-13Nb-13Zr alloy, mechanically pre-treated, degreased, etched and rinsed in demineralised water is placed in the anodising bath containing 0.01 mol ⁇ dm -3 Ca(H 2 PO 2 ) 2 and the suspension of 100 g ⁇ dm -3 Cu 3 (PO 4 ) 2 . After placing the implant in the bath, the electrolytic plasma oxidation process is carried out by polarizing it with the anodic current density of 100 mA ⁇ cm -2 . The process is carried out for 7 minutes, with the maximum voltage of 350 V. After the process, the implant is rinsed in demineralised water and air-dried at 45°C.
- Example III The implant made of Ti-15Mo alloy, mechanically pre-treated, degreased, etched and rinsed in demineralised water is placed in the anodising bath containing 5 mol ⁇ dm -3 Ca(H 2 PO 2 ) 2 and the suspension of 200 g ⁇ dm -3 Zn 3 (PO 4 ) 2 . After placing the implant in the bath, the electrolytic plasma oxidation process is carried out by polarizing it with the anodic current density of 200 mA ⁇ cm -2 . The process is carried out for 5 minutes, with the maximum voltage of 400 V. After the process, the implant is rinsed in demineralised water and air-dried at 45°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Prostheses (AREA)
- Chemical Treatment Of Metals (AREA)
- Materials For Medical Uses (AREA)
Claims (1)
- Verfahren zur Oberflächenmodifizierung von Titan durch plasmaelektrochemische Oxidation in wässrigen Ca(H2PO2)2-Bädern mit einer Konzentration von 0,01 mol/dm-3 bis 5 mol/dm-3 mit einer anodischen Stromdichte von 1 mA/cm-2 bis 250 mA/cm-2 und einer angelegten Spannung von 50 V bis 600 V durch Eintauchen des Elements, dessen Oberfläche modifiziert werden soll, in die wässrige Ca(H2PO2)2-Lösung, dadurch gekennzeichnet, dass das Bad unlösliche Metallphosphatteilchen in einer Konzentration von 1 g/dm-3 bis 400 g/dm-3 enthält, und die wässrige Salzlösung Kupfer(II)-phosphat Cu3(PO4)2 in einer Konzentration von 1 g/dm-2 bis 400 g/dm-3 oder die wässrige Salzlösung Silber(l)-phosphat Ag3PO4 in einer Konzentration von 1 g-dm" bis 400 g-dm" oder die wäßrige Salzlösung Zinkphosphat Zn3(PO4)2 in einer Konzentration von 1 g/dm-3 bis 400 g/dm-3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL430374A PL239584B1 (pl) | 2019-06-25 | 2019-06-25 | Sposób otrzymywania porowatych powłok antybakteryjnych na powierzchni tytanu i jego stopów |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3816327A1 EP3816327A1 (de) | 2021-05-05 |
EP3816327B1 true EP3816327B1 (de) | 2023-10-18 |
EP3816327B8 EP3816327B8 (de) | 2023-12-20 |
Family
ID=69740320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20460021.7A Active EP3816327B8 (de) | 2019-06-25 | 2020-05-05 | Verfahren zur herstellung von porösen antibakteriellen beschichtungen auf der oberfläche von titan und titanlegierungen |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3816327B8 (de) |
PL (2) | PL239584B1 (de) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL240205B1 (pl) * | 2019-06-23 | 2022-02-28 | Osteoplant Res And Development Spolka Z Ograniczona Odpowiedzialnoscia | Sposób modyfikacji powierzchni implantów z tytanu lub stopów tytanu |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL128024B1 (en) | 1980-06-26 | 1983-12-31 | Ct Kt Maszyn Gorniczych Komag | Mechanized roof support of high supporting capacity |
PL128693B1 (en) | 1980-06-26 | 1984-02-29 | Zaklady Wytworcze Urzadzen Syg | Stabilized power pack |
RU2075872C1 (ru) * | 1994-07-27 | 1997-03-20 | Институт химии Дальневосточного отделения РАН | Электролит для микродугового оксидирования титана и его сплавов |
CN101899700B (zh) | 2009-05-25 | 2011-12-07 | 佳木斯大学 | 镁、钛表面超声微弧氧化载银抗菌生物活性涂层制备方法 |
PL214958B1 (pl) * | 2010-03-22 | 2013-10-31 | Politechnika Slaska Im Wincent | Sposób modyfikacji warstwy wierzchniej tytanu i jego stopów fosforem lub wapniem i fosforem metodą elektrochemicznego utleniania plazmowego |
PL214630B1 (pl) | 2010-03-22 | 2013-08-30 | Politechnika Slaska Im Wincent | Sposób modyfikacji warstwy wierzchniej stopów tytanu typu Ti-xNb-yZr wapniem lub wapniem i fosforem metodą elektrochemicznego utleniania plazmowego |
PL396115A1 (pl) | 2011-08-29 | 2013-03-04 | Politechnika Slaska | Sposób pasywacji anodowej bezwanadowych stopów tytanu typu Ti-xNb-yZr |
CN102677125B (zh) * | 2012-06-13 | 2014-12-17 | 西北有色金属研究院 | 钛及钛合金医疗器械表面活性抗菌复合涂层的制备方法 |
CN103526261A (zh) | 2013-10-17 | 2014-01-22 | 赵全明 | 一种含锌微弧氧化电解液及其含锌生物陶瓷膜的制备方法 |
CN103911644B (zh) | 2014-04-09 | 2016-10-05 | 江西科技师范大学 | 钛合金微弧氧化电解液及微弧氧化方法 |
CN107376897B (zh) | 2017-06-27 | 2020-02-18 | 华南理工大学 | 一种含有三金属的氧化催化膜及其制备方法与应用 |
CN108543109B (zh) | 2018-03-13 | 2020-09-18 | 淮阴工学院 | 低磨双重抗菌钛基纳米复合材料骨植入体及其成形方法 |
-
2019
- 2019-06-25 PL PL430374A patent/PL239584B1/pl unknown
-
2020
- 2020-05-05 EP EP20460021.7A patent/EP3816327B8/de active Active
- 2020-05-05 PL PL20460021.7T patent/PL3816327T3/pl unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL240205B1 (pl) * | 2019-06-23 | 2022-02-28 | Osteoplant Res And Development Spolka Z Ograniczona Odpowiedzialnoscia | Sposób modyfikacji powierzchni implantów z tytanu lub stopów tytanu |
Also Published As
Publication number | Publication date |
---|---|
PL3816327T3 (pl) | 2024-03-18 |
PL239584B1 (pl) | 2021-12-20 |
PL430374A1 (pl) | 2020-07-13 |
EP3816327A1 (de) | 2021-05-05 |
EP3816327B8 (de) | 2023-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Durdu et al. | The tribological properties of bioceramic coatings produced on Ti6Al4V alloy by plasma electrolytic oxidation | |
US8545559B2 (en) | Modified metal materials, surface modifications to improve cell interactions and antimicrobial properties, and methods for modifying metal surface properties | |
KR100910064B1 (ko) | 항균성 및 생체적합성이 우수한 임플란트재료 및 그 제조방법 | |
Makurat-Kasprolewicz et al. | Recent advances in electrochemically surface treated titanium and its alloys for biomedical applications: A review of anodic and plasma electrolytic oxidation methods | |
Harun et al. | Hydroxyapatite-based coating on biomedical implant | |
Fialho et al. | Surface engineering of nanostructured Ta surface with incorporation of osteoconductive elements by anodization | |
Kazek-Kęsik et al. | Surface characterisation of Ti–15Mo alloy modified by a PEO process in various suspensions | |
US20210338889A1 (en) | Implant with ceramic coating, method of forming an implant, and method of applying a ceramic coating | |
Simka et al. | Modification of a Ti–Mo alloy surface via plasma electrolytic oxidation in a solution containing calcium and phosphorus | |
de Viteri et al. | Structure, tribocorrosion and biocide characterization of Ca, P and I containing TiO2 coatings developed by plasma electrolytic oxidation | |
Simka et al. | Formation of bioactive coatings on Ti–13Nb–13Zr alloy for hard tissue implants | |
WO2020067500A1 (ja) | 抗菌材、積層体、抗菌性積層体、医療用部材、抗菌材の製造方法、抗菌性積層体の製造方法及び抗菌方法 | |
CN108939155A (zh) | 一种镁基组织工程材料抗菌涂层及其制备方法 | |
EP3757257B1 (de) | Verfahren zur herstellung von porösen antibakteriellen beschichtungen auf der oberfläche von titan und titanlegierungen | |
Mahmud et al. | Recent developments in hydroxyapatite coating on magnesium alloys for clinical applications | |
Mousa et al. | Surface modification of magnesium and its alloys using anodization for orthopedic implant application | |
Safavi et al. | Improved osteogenic activity of NiTi orthopedic implant by HAp-Nb2O5 composite coatings: Materials and biological points of view | |
Jarosz et al. | Anodization of titanium alloys for biomedical applications | |
EP3816327B1 (de) | Verfahren zur herstellung von porösen antibakteriellen beschichtungen auf der oberfläche von titan und titanlegierungen | |
Peng et al. | Hydrothermal growth of hydroxyapatite and ZnO bilayered nanoarrays on magnesium alloy surface with antibacterial activities | |
TWI532883B (zh) | 具有抗菌表面之鈦或鈦合金及其製作方法 | |
Acar et al. | Improving the wettability and corrosion behavior of Cp-Ti by applying anodization surface treatment with the addition of boric acid, graphene oxide and hydroxyapatite | |
Kazek‐Kęsik et al. | In vitro bioactivity investigations of T i‐15 M o alloy after electrochemical surface modification | |
Kim et al. | Effect of surface pretreatment and pack cementation on bioactivity of titanium dental implant | |
Vangolu et al. | Corrosion and wear performances of hydroxyapatite and boron-containing TiO2 composite coatings on Ti6Al7Nb alloy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211027 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230322 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020019409 Country of ref document: DE |
|
GRAT | Correction requested after decision to grant or after decision to maintain patent in amended form |
Free format text: ORIGINAL CODE: EPIDOSNCDEC |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG PRIORITAET |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20231018 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1622537 Country of ref document: AT Kind code of ref document: T Effective date: 20231018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240218 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240119 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240118 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240118 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20240123 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240426 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018 |